Form D of The Day: Ribon Therapeutics $23.50 million Financing. Victoria M Richon Published Nov 18 SEC Filing

Biotechnology Ribon Therapeutics, Inc. - Victoria M Richon

Ribon Therapeutics Financing

Ribon Therapeutics, Inc., Corporation just had published form D because of $23.50 million equity financing. The date of first sale was 2015-11-19. Ribon Therapeutics was able to finance itself with $23.50 million. That is 100.00% of the financing round. The total private financing amount was $23.50 million. The financing document was filed on 2016-11-18. The reason for the financing was: unspecified.

Ribon Therapeutics is based in Massachusetts. The company’s business is Biotechnology. The form was submitted by Victoria M Richon President. The company was incorporated in 2015. The filler’s address is: 99 Hayden Avenue, Building D, Suite 100, Lexington, Ma, Massachusetts, 02421. Laurence Lasky is the related person in the form and it has address: 99 Hayden Avenue, Building D, Suite 100, Lexington, Ma, Massachusetts, 02421. Link to Ribon Therapeutics Filing: 000166041016000002.

Analysis of Ribon Therapeutics Offering

On average, firms in the Biotechnology sector, sell 73.77% of the total offering amount. Ribon Therapeutics sold 100.00% of the offering. Could this mean that the trust in Ribon Therapeutics is high? The average investment offering size for companies in the Biotechnology industry is $3.08 million. The total amount raised is 662.99% bigger than the average for companies in the Biotechnology sector. The minimum investment for this financing was set at $0. If you know more about the reasons for the financing, please comment below.

What is Form D? What It Is Used For

Form D disclosures could be used to track and understand better your competitors. The information in Form D is usually highly confidential for ventures and startups and they don’t like revealing it. This is because it reveals amount raised or planned to be raised as well as reasons for the financing. This could help competitors. Entrepreneurs usually want to keep their financing a ‘secret’ so they can stay in stealth mode for longer.

Why Fundraising Reporting Is Good For Ribon Therapeutics Also

The Form D signed by Victoria M Richon might help Ribon Therapeutics, Inc.’s sector. First, it helps potential customers feel more safe to deal with a firm that is well financed. The odds are higher that it will stay in the business. Second, this could attract other investors such as venture-capital firms, funds and angels. Third, positive PR effects could even bring leasing firms and venture lenders.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Related posts

Leave a Comment